Claims for Patent: 5,968,825

Summary for Patent: 5,968,825

Title:	Antisense oligonucleotides complementary to the primary transcript of the human c-fes protooncogene
Abstract:	The following description sets forth antisense (AS) oligonucleotides (ODNs) complementary to the primary transcript of the human c-fes protooncogene and their use to inactivate said transcript. All-trans retinoic acid (ATRA) is reported to be used as a differentiation inducer on cells pretreated with said AS-ODNs to induce apoptosis of leukemic blast cells.
Inventor(s):	Ferrari; Sergio (Modena, IT), Manfredini; Rossella (Campogalliano, IT)
Assignee:	Istituto Biochimico Italiano Giovanni Lorenzini S.P.A. (Milan, IT)
Application Number:	08/859,389
Patent Claims:	1. An antisense oligonucleotide complementary to the primary transcript of human c-fes protooncogene, which hybridizes to said primary transcript at a sequence spanning to the exon 2/intron 2 or the exon 3/intron 3 splice junction. 2. The antisense oligonucleotide of claim 1, which includes the sequence shown in SEQ ID NO:1 or SEQ ID NO:2. 3. The antisense oligonucleotide of claim 1, which is modified and stabilized to prolong its half-life. 4. The antisense oligonucleotide of claim 3, modified at its 3' or 5' end with a phosphorothionate derivative. 5. The antisense oligonucleotide of claim 3, wherein its internucleotide phosphate bridge is a methylphosphonate, phosphorothionate, phosphorodithionate, or phosphate ester group. 6. The antisense oligonucleotide of claim 3, which is complexed noncovalently with transeferrin-polylysine. 7. A method for inhibiting expression of c-fes protein in a cell comprising administering to the cell at least one antisense oligonucleotide complementary to the primary transcript of the human c-fes protooncogene, wherein said antisense oligonucleotide hybridizes with said primary transcript at a sequence spanning to the exon 2/intron 2 or the exon 3/intron 3-splice junction. 8. The method of claim 7, wherein said antisense oligonucleotide includes the sequence shown in SEQ ID NO:1 or SEQ ID NO:2. 9. The method of claim 7, further comprising administering to said cells all-trans retinoic acid to induce cell differentiation and apoptosis.

Details for Patent 5,968,825

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-05-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-05-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-05-20